Financial equity analysts and institutional research firms tracking ImmunityBio, trading under the ticker IBRX, maintain consensus price targets that fluctuate based on clinical milestone achievements, regulatory updates, and quarterly financial disclosures. Current average forecasts for the stock cluster around the 14.20 US dollar mark, reflecting varied outlooks among Wall Street professionals. These targets are continuously revised in response to the commercial rollout and adoption rates of its FDA-approved immunotherapy treatments, ongoing clinical trial readouts across combination oncology pipelines, and the company's overall capital expenditure and debt management strategies.